Hong Kong-listed Hansoh Pharmaceutical (3692.HK) said on Tuesday that its B7-H3-directed antibody-drug conjugate, HS-20093, met the primary endpoint in a late-stage clinical trial.
The company said the drug showed a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy.
